-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70

Benzinga·11/04/2026 17:22:03
Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.